Targeted peptide therapy to promote collagen synthesis, accelerate wound healing, and improve skin quality — prescribed by Australian doctors.
Skin quality, wound healing, and connective tissue integrity are governed by collagen synthesis, angiogenesis, and cellular repair — all processes that can be targeted with peptide therapy. Unlike topical skincare products that act on the surface, peptide therapy acts systemically at the cellular level.
GHK-Cu (copper peptide GHK-Cu) is the primary agent in this program. It is a naturally occurring human tripeptide with extensive preclinical and clinical data supporting its role in collagen and elastin synthesis, wound healing, anti-inflammatory activity, and skin remodelling. It can be administered subcutaneously for systemic effect or formulated topically by our pharmacy for targeted application.
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, urine, and saliva. Plasma concentrations peak at approximately 200 ng/mL in young adults and decline with age. It was first identified in 1973 and has been one of the most extensively studied naturally occurring peptides in dermatology and wound healing.
GHK-Cu's mechanisms include stimulation of collagen and glycosaminoglycan synthesis, upregulation of angiogenesis genes, activation of antioxidant defences, and modulation of inflammatory pathways. It also has documented effects on skin thickness, wrinkle reduction, and improved skin elasticity in clinical studies.
It can be formulated for subcutaneous injection (systemic effects) or as a topical cream/serum by our compounding pharmacy, depending on the clinical indication.
Prescription and pharmacy dispatch. Subcutaneous and topical formulations are prepared to order by Epsilon Pharma.
Improved skin hydration, texture, and early signs of improved elasticity are typically reported in this window.
More significant skin firmness and quality improvements. Wound healing and scar remodelling progress meaningfully during this phase.
Maximum skin quality benefit for most patients. Maintenance dosing discussed with your doctor based on your response.
Check your eligibility and book your consultation with a Natura doctor.
GHK-Cu is an unregistered medicine when prescribed for systemic peptide therapy in Australia. Prescribed under TGA prescribing authority by AHPRA-registered doctors and compounded by TGO 101-compliant pharmacists. Individual results may vary. Not suitable for patients with Wilson's disease or active cancer. Not suitable for patients under 18.